StemSight secures new patents for scalable induced pluripotent stem cells-derived limbal stem cells, boosting STE-101’s path to off-the-shelf limbal stem cell deficiency therapy and upcoming Series A.
Abigail Lewis, Content Intern
Advertisement
Contact me!
Email: alewis@mjhlifesciences.com
Articles by Abigail Lewis, Content Intern
The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Modern Retina
1
CTS 2026: OTX-TKI demonstrates superiority over aflibercept in wet AMD—what the SOL-1 data mean for retina practice
2
Ranluspec FDA approval: Cyrus Karkaria, PhD, on biosimilar access, prefilled syringes, and long-term switching confidence
3
The Retina TL;DR with Dr. Weng: Clinical trials, career, and community with David A. Eichenbaum, MD, FASRS
4
Geographic atrophy: When lesion borders cannot be graded
5